aTYR PHARMA (ATYR) Receivables - Other (2019 - 2026)

aTYR PHARMA (ATYR) has reported Receivables - Other for 8 consecutive years, with $426000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Receivables - Other fell 14.46% year-over-year to $426000.0; the trailing twelve-month figure through Jun 2026 stood at $426000.0 (down 14.46% YoY), and the FY2025 full-year result was $873000.0, down 49.71% from the prior year.
• Receivables - Other fell to $426000.0 in Q2 2026 per ATYR's latest filing, from $477000.0 in the prior quarter.
• Across five years, Receivables - Other topped out at $11.8 million in Q4 2022 and bottomed at -$9.9 million in Q1 2023.
• Historically, Receivables - Other has averaged $919500.0 across 5 years, with a median of $685500.0 in 2022.
• The sharpest annual moves came in 2022 and 2023: Receivables - Other surged 3748.04% in 2022, then plunged 2419.95% in 2023.
• Over 5 years, Receivables - Other stood at $11.8 million in 2022, then slumped by 96.11% to $458000.0 in 2023, then sank by 120.74% to -$95000.0 in 2024, then plunged by 77.89% to -$169000.0 in 2025, then surged by 352.07% to $426000.0 in 2026.
• According to Business Quant data, Receivables - Other over the past three periods registered $426000.0, $477000.0, and -$169000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.